Jacobs Levy Equity Management Inc. Grows Position in Maravai LifeSciences Holdings, Inc. $MRVI

Key Points

• Jacobs Levy Equity Management Inc. significantly increased its holdings in Maravai LifeSciences by 437.0% during the first quarter, acquiring an additional 401,673 shares.
• Analysts remain cautious, with Royal Bank of Canada lowering the price target for Maravai LifeSciences from $7.00 to $5.00, while the company holds a consensus rating of "Hold".
• As of now, institutional investors own over 50% of Maravai LifeSciences' stock, reflecting significant confidence in the company despite recent stock performance volatility.

Jacobs Levy Equity Management Inc. boosted its holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 437.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 493,582 shares of the company's stock after acquiring an additional 401,673 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 0.19% of Maravai LifeSciences worth $1,091,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in MRVI. EntryPoint Capital LLC purchased a new position in shares of Maravai LifeSciences in the 1st quarter valued at about $32,000. Teacher Retirement System of Texas purchased a new position in shares of Maravai LifeSciences in the 1st quarter valued at about $37,000. Aigen Investment Management LP purchased a new position in shares of Maravai LifeSciences in the 1st quarter valued at about $37,000. Performa Ltd US LLC increased its holdings in shares of Maravai LifeSciences by 245.0% in the 1st quarter. Performa Ltd US LLC now owns 17,250 shares of the company's stock valued at $38,000 after purchasing an additional 12,250 shares in the last quarter. Finally, Pekin Hardy Strauss Inc. purchased a new position in shares of Maravai LifeSciences in the 1st quarter valued at about $55,000. Hedge funds and other institutional investors own 50.25% of the company's stock.

Maravai LifeSciences Stock Performance

NASDAQ:MRVI opened at $2.79 on Friday. The company has a current ratio of 5.16, a quick ratio of 4.49 and a debt-to-equity ratio of 0.68. The firm has a 50-day moving average price of $2.49 and a two-hundred day moving average price of $2.34. Maravai LifeSciences Holdings, Inc. has a twelve month low of $1.66 and a twelve month high of $9.50. The company has a market capitalization of $712.45 million, a P/E ratio of -2.05 and a beta of 0.29.

Analyst Upgrades and Downgrades

Separately, Royal Bank Of Canada cut their price target on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating for the company in a report on Tuesday, August 12th. Three analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $5.22.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.